Steve Clifford

Professor of Childhood Cancer Research and Director of the Newcastle University Centre for Cancer @NU_Cancer. Views are my own.

[Steve Clifford @ProfSClifford]

You can also find me - and a rapidly growing number of interesting cancer folk - on Bluesky Social
@ProfSClifford.bsky.social

[Steve Clifford @ProfSClifford]

Merry Christmas Everyone!
This year, instead of Christmas cards, I’ve donated to the wonderful ‘Children with Cancer in Malawi’ charity https://t.co/ijadOQSuPD. You could do the same if you’re interested?!
Wishing you all a happy and healthy 2026!

[Newcastle University Centre for Cancer @NU_Cancer]

We're delighted to share that @UniofNewcastle has officially approved renewal of the #NUCancerCentre for 2025-30.

We look forward to continuing this important journey together over the next five years.

[Steve Clifford @ProfSClifford]

I’m pleased to be speaking at the @CRUKresearch’s upcoming children’s & young people’s cancers webinar on exploring further discoveries from clinical research. Join me on 12 February from 3–4:30 pm (GMT): https://t.co/08KzPvXk9j @NU_Cancer

[Science and Innovation at Cancer Research UK @CRUKresearch]

🚨 Less than one week left until our #ExploringCYPCancers webinar. Join researchers at the interface between clinical & discovery research discussing how to learn more from #ClinicalTrials to improve outcomes for children’s & young people’s cancers 👉 https://t.co/7M0y90WB3a

[Science and Innovation at Cancer Research UK @CRUKresearch]

📣Announcing more speakers at our upcoming #ExploringCYPCancers webinar on clinical research:

💡Steve Clifford (@NU_Cancer)
💡John Rainsbury (Little Hero)

Join us on 12 Feb, 3–4:30 pm to explore how to maximise learning from #ClinicalTrials: https://t.co/JUTZtir3ZQ

@ProfSClifford | @UniofNewcastle | @JohnRainsbury

[Steve Clifford @ProfSClifford]

PhD post available: Are you interested in using contemporary ‘omics approaches to uncover clinically-relevant biology in medulloblastoma, the most common malignant brain tumour in children? Join our Childhood Brain Tumour Research team @nu_cancer
See https://t.co/C6wOJvRVSI

[Steve Clifford @ProfSClifford]

PhD post available: Are you interested in using contemporary ‘omics approaches to uncover clinically-relevant biology in medulloblastoma, the most common malignant brain tumour in children? Join our Childhood Brain Tumour Research team @nu_cancer
See https://t.co/C6wOJvRVSI

[Steve Clifford @ProfSClifford]

Looking for a PhD? Our multi-disciplinary team @NU_Cancer are using next-generation 'omics, AI, bioinformatics and biostatistics across pan-European clinical trials to improve outcomes for children with #medulloblastoma. See https://t.co/IhAK1j3w4m or DM if you're interested.

[Steve Clifford @ProfSClifford]

Looking for a PhD? Our multi-disciplinary team @NU_Cancer are using next-generation 'omics, AI, bioinformatics and biostatistics across pan-European clinical trials to improve outcomes for children with #medulloblastoma. See https://t.co/IhAK1j3w4m or DM if you're interested.

[Debbie Hicks @debbiehicksNCL]

Exciting PhD opportunity seeking to reduce the therapy-associated late-effects burden in childhood cancer survivors, in our internationally-leading childhood cancer centre!
@NU_Cancer

@ChildCancerNTH

@halsey_lab

@DelFred010530 https://t.co/BshikVVmlG

[Newcastle University @UniofNewcastle]

We're proud to announce over 700 scholarships for international and EU students, welcoming applications from students of diverse backgrounds from across the world to support them in pursuing their degrees! 🎺🌎

Read more here. ⬇

#WeAreNCL

https://t.co/Ny4H4m96oO

[Newcastle University @UniofNewcastle]

Vital research led by our own Professor Steve Clifford could lead to treatments that improve survival rates of children diagnosed with Medulloblastoma, which is responsible for around 5% to 10% of childhood cancer deaths. 🔬

Read more here. ⬇

#WeAreNCL

https://t.co/4Isr6PRpKp

[Steve Clifford @ProfSClifford]

Studies find more targeted approach to treating childhood brain cancer https://t.co/8VKQXd093k @NU_Cancer @UniofNewcastle @NCL_medscience @SIOPEurope @CCLG_UK @ITCC_eu

[Steve Clifford @ProfSClifford]

Out now.....MYC-dependent upregulation of the serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma https://t.co/8ncDnvhL6n Great job Maggie and our amazing collabs @NU_Cancer @CwC_UK @BrainTumourOrg @GOSHCharity @ChildCancerNTH

[Steve Clifford @ProfSClifford]

Just published 2: Heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcome - picking out the bad actors from >1600 patients https://t.co/37k3c9RFlW Well done @edschwalbe et al @NU_Cancer @CRUKresearch @CwC_UK @BrainTumourOrg @GOSHCharity

[Steve Clifford @ProfSClifford]

Revealing the 'worst of the worst' #medulloblastoma - new treatments urgently needed: Heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcome https://t.co/37k3c9RFlW @edschwalbe @NU_Cancer @CRUKresearch @CwC_UK @BrainTumourOrg @GOSHCharity

[Steve Clifford @ProfSClifford]

Out now.....MYC-dependent upregulation of the serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma https://t.co/8ncDnvhL6n Great job Maggie and our amazing collabs @NU_Cancer @CwC_UK @BrainTumourOrg @GOSHCharity @ChildCancerNTH

[Steve Clifford @ProfSClifford]

If you don't know..... @rushtheband

[Steve Clifford @ProfSClifford]

If you know.....

[Steve Clifford @ProfSClifford]

If you know.....